Hoffnung stirbt zum Schluss...!
Seite 4 von 25 Neuester Beitrag: 25.04.21 00:48 | ||||
Eröffnet am: | 12.09.13 19:00 | von: raurunter | Anzahl Beiträge: | 623 |
Neuester Beitrag: | 25.04.21 00:48 | von: Kathrinencya | Leser gesamt: | 96.395 |
Forum: | Hot-Stocks | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 25 > |
http://www.cancer.gov/drugdictionary?cdrid=346914
DJ-927
A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic properties. Oral taxane derivative DJ-927 binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. As the first oral taxane derivative, oral taxane derivative DJ-927 is more potent than paclitaxel and docetaxel. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym: oral taxane derivative DJ-927
Code name: DJ927
Breast Diseases 2 studies
Breast Neoplasms 2 studies
Carcinoma 5 studies
Carcinoma, Transitional Cell 1 study
Colonic Diseases 1 study
Colonic Neoplasms 1 study
Colorectal Neoplasms 1 study
Digestive System Diseases 4 studies
Digestive System Neoplasms 4 studies
Gastrointestinal Diseases 4 studies
Gastrointestinal Neoplasms 4 studies
Genital Diseases, Male 1 study
Genital Neoplasms, Male 1 study
Intestinal Diseases 1 study
Intestinal Neoplasms 1 study
Lymphoma 1 study
Melanoma 2 studies
Neoplasms, Germ Cell and Embryonal 2 studies
Neoplasms, Glandular and Epithelial 5 studies
Neoplasms, Nerve Tissue 2 studies
Neuroectodermal Tumors 2 studies
Neuroendocrine Tumors 2 studies
Neuroepithelioma 2 studies
Nevus 2 studies
Nevus, Pigmented 2 studies
Prostatic Diseases 1 study
Prostatic Neoplasms 1 study
Rectal Diseases 1 study
Skin Diseases 2 studies
Stomach Carcinoma 3 studies
Stomach Diseases 3 studies
Stomach Neoplasms 3 studies
Transitional Cell Carcinoma 1 study
Urinary Bladder Diseases 1 study
Urinary Bladder Neoplasms 1 study
Urogenital Neoplasms 2 studies
Urologic Diseases 1 study
Urologic Neoplasms 1 study
http://www.clinicaltrials.gov/ct2/results/...amp;brwse=cond_alpha_all
Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A.
Author information
Abstract
DJ-927 is a novel taxane, which was selected for high solubility, non-neurotoxicity, oral bioavailability, and potent antitumor activity. In this study, we compared the in vitro and in vivo efficacy of DJ-927 with those of paclitaxel and docetaxel. DJ-927 exhibited stronger cytotoxicity than paclitaxel and docetaxel in various tumor cell lines, especially against P-glycoprotein (P-gp)-expressing cells. The cytotoxicity of DJ-927, unlike those of other taxanes, was not affected by the P-gp expression level in tumor cells, or by the co-presence of a P-gp modulator. When intracellular accumulation of the three compounds was compared, intracellular amounts of DJ-927 were much higher than those of paclitaxel or docetaxel, particularly in P-gp-positive cells. In vivo, DJ-927 showed potent antitumor effects against two human solid tumors in male BALB/c-nu/nu mice, and yielded significant life-prolongation in a murine liver metastasis model with male C57BL/6 mice, in which neither paclitaxel nor docetaxel was effective. The results demonstrate the superior efficacy of orally administered DJ-927 over intravenously administered paclitaxel or docetaxel against P-gp-expressing tumors, probably due to higher intracellular accumulation. A phase I clinical trials of DJ-927 is currently ongoing in the US.
Adenocarcinoma 4 studies
Adenoma 1 study
Adenoma, Islet Cell 1 study
Adenoviridae Infections 1 study
Angiomatosis 1 study
Apudoma 2 studies
Arterial Occlusive Diseases 2 studies
Arteriosclerosis 2 studies
Arthritis 1 study
Arthritis, Rheumatoid 1 study
Atherosclerosis 2 studies
Autoimmune Diseases 1 study
B-cell Lymphomas 1 study
Bacterial Infections 1 study
Blood Coagulation Disorders 1 study
Blood Protein Disorders 1 study
Body Temperature Changes 1 study
Body Weight 1 study
Brain Diseases 3 studies
Brain Neoplasms 2 studies
Brain Tumor, Childhood 1 study
Breast Diseases 1 study
Breast Neoplasms 1 study
Carcinoid Tumor 3 studies
Carcinoma 7 studies
Carcinoma, Islet Cell 1 study
Carcinoma, Neuroendocrine 3 studies
Carcinoma, Squamous Cell 1 study
Carotid Artery Diseases 1 study
Cataract 1 study
Central Nervous System Diseases 3 studies
Central Nervous System Neoplasms 2 studies
Cerebrovascular Disorders 1 study
Chorioretinitis 1 study
Choroid Diseases 1 study
Choroiditis 1 study
Connective Tissue Diseases 1 study
Coronary Artery Disease 1 study
Coronary Disease 1 study
Cranial Nerve Diseases 1 study
Craniomandibular Disorders 1 study
Cystic Fibrosis 1 study
Digestive System Diseases 7 studies
Digestive System Neoplasms 5 studies
Endocrine Gland Neoplasms 6 studies
Endocrine System Diseases 6 studies
Eye Diseases 1 study
Facial Nerve Diseases 1 study
Facial Neuralgia 1 study
http://www.clinicaltrials.gov/ct2/...=%22Digestive+System+Diseases%22
http://www.ncbi.nlm.nih.gov/pubmed/22900955
auf den Konto ist. Mehr kann man nicht mehr tun.
Wer aber es gerne heiß mag der kann auch bei NeoMedia AG einsteigen.
Das ist für mich die heißeste Aktie die ich je hatte.
Bis dahin ist Genta längst abgewickelt.
Hat keinen Sinn mehr. Musste es schmerzhaft eingestehen.
Zeit hier noch verplembern. Kopf hoch und eingestehen was nicht mehr
zu ändern ist. Es gibt noch andere Aktien.
London - Im Jahr 2012 erkrankten 14 Millionen Menschen weltweit neu an Krebs, die Zahl der Betroffenen soll in den nächsten Jahren noch drastisch steigen. Dies ist das Ergebnis des aktuellen Welt-Krebsberichts 2014 der Weltgesundheitsorganisation WHO. Vor allem in Entwicklungsländern könnte demnach der Zugang zu bezahlbaren und effektiven Behandlungsmöglichkeiten vielen Krebskranken das Leben retten.
Quelle:
http://www.spiegel.de/gesundheit/diagnose/...vermeidbar-a-950813.html